Steven Perrin, Ph.D.

Steven Perrin, Ph.D.

President and Chief Scientific OfficeratEledon Pharmaceuticals· In proxies 2022–2025

Pay in FY2025-63% from the year before · Eledon Pharmaceuticals stock -63.3% the same year

Steven Perrin, Ph.D. was paid $1.7M in FY2025 (Dec), down 63%. Eledon Pharmaceuticals stock fell 63.3% that year.

Pay$100 in the stock at the end of FY21 → $34
Pay is from the Summary Compensation Table of each Eledon Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Eledon PharmaceuticalsPublic company · 4 yr
    • President and Chief Scientific Officer2022 – Present · 4 yrStock in role -39%
  2. Anelixis TransactionPublic company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Eledon PharmaceuticalsDirector · 5 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?